Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Antibodies targeting chemokine receptors CXCR4 and ACKR3.

Bobkov V, Arimont M, Zarca A, De Groof T, van der Woning B, de Haard H, Smit MJ.

Mol Pharmacol. 2019 Sep 3. pii: mol.119.116954. doi: 10.1124/mol.119.116954. [Epub ahead of print]

2.

Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.

De Groof TWM, Mashayekhi V, Fan TS, Bergkamp ND, Sastre Toraño J, van Senten JR, Heukers R, Smit MJ, Oliveira S.

Mol Pharm. 2019 Jul 1;16(7):3145-3156. doi: 10.1021/acs.molpharmaceut.9b00360. Epub 2019 Jun 19.

3.

Nanobodies detecting and modulating GPCRs outside in and inside out.

Heukers R, De Groof TWM, Smit MJ.

Curr Opin Cell Biol. 2019 Apr;57:115-122. doi: 10.1016/j.ceb.2019.01.003. Epub 2019 Mar 5. Review.

PMID:
30849632
4.

Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.

De Groof TWM, Bobkov V, Heukers R, Smit MJ.

Mol Cell Endocrinol. 2019 Mar 15;484:15-24. doi: 10.1016/j.mce.2019.01.021. Epub 2019 Jan 26. Review.

5.

The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth.

Heukers R, Fan TS, de Wit RH, van Senten JR, De Groof TWM, Bebelman MP, Lagerweij T, Vieira J, de Munnik SM, Smits-de Vries L, van Offenbeek J, Rahbar A, van Hoorick D, Söderberg-Naucler C, Würdinger T, Leurs R, Siderius M, Vischer HF, Smit MJ.

Oncogene. 2018 Jul;37(30):4110-4121. doi: 10.1038/s41388-018-0255-7. Epub 2018 Apr 30.

Supplemental Content

Loading ...
Support Center